Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Core Viewpoint - Savara Inc. has resubmitted the MOLBREEVI Biologics License Application (BLA) to the FDA for the treatment of autoimmune PAP, a rare lung disease [1] Group 1: Company Developments - The resubmission of the MOLBREEVI BLA is in collaboration with Fujifilm as the drug substance manufacturer [1] - The treatment targets autoimmune PAP, which is characterized by the abnormal build-up of surfactant in the alveoli [1]